|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2001-7-4
|
|
pubmed:abstractText |
To assess the cost and effectiveness of adding a system of polymerase chain reaction (PCR) testing to the current enzyme-linked immunosorbent assay (ELISA) screening for hepatitis C virus (HCV) in blood donations.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0042-9007
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
80
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
199-204
|
|
pubmed:dateRevised |
2011-1-11
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Including polymerase chain reaction in screening for hepatitis C virus RNA in blood donations is not cost-effective.
|
|
pubmed:affiliation |
Institut National de la Santé et de la Recherche Médicale INSERM U379, Marseille, France. loubiere@marseille.inserm.fr
|
|
pubmed:publicationType |
Journal Article
|
